What are the active ingredients in Mounjaro?
- AJ Hill Aesthetics

- Oct 23
- 3 min read

The active ingredient in Mounjaro is tirzepatide, a man-made version of two natural hormones called GIP and GLP-1. These hormones help regulate blood sugar and appetite, so tirzepatide works by enhancing your body’s own ability to manage these processes. What makes Mounjaro unique is that it targets both hormone pathways at once, which is thought to contribute to its effects on blood sugar control and weight management.
Understanding how tirzepatide works in the body

Tirzepatide is described by NICE as a “dual GIP and GLP-1 receptor agonist.” These two hormones—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)—are naturally released from the gut after eating. They signal the pancreas to release insulin when blood sugar rises and also slow the rate at which food leaves the stomach. By mimicking both signals, tirzepatide helps regulate glucose levels more effectively while also reducing hunger. According to NHS guidance, this dual action allows Mounjaro to support both diabetes management and healthy weight reduction when used alongside diet and physical activity.
What makes tirzepatide different from other medicines
Before Mounjaro, most injectable weight-management medicines in the UK acted only on GLP-1 receptors, such as semaglutide (Wegovy). Tirzepatide’s addition of GIP activity represents a new therapeutic category that NICE (TA1026, 2025) refers to as “first-in-class.” The GIP pathway appears to improve how the body responds to insulin and may balance some of the nausea linked to GLP-1 drugs. Early clinical studies published in The Lancet Diabetes & Endocrinology and Nature Medicine found that participants receiving tirzepatide achieved greater average weight reduction than those on semaglutide in similar trials, while maintaining comparable safety profiles.
Why Mounjaro influences appetite and digestion

One reason Mounjaro affects appetite is its role in slowing gastric emptying—the time it takes food to move from the stomach to the intestines. This delay helps people feel fuller for longer after meals. NICE explains that this is part of how GLP-1–based therapies encourage portion control. Tirzepatide enhances this process through the combined effect of GIP and GLP-1 signalling. Some people have found it helpful to eat smaller, more frequent meals in the early weeks, giving their digestion time to adapt to the slower pace. NHS specialists often advise this practical approach to reduce bloating and improve comfort while staying on track with balanced nutrition.
Safety, formulation, and other ingredients
While tirzepatide is the active ingredient, the pre-filled injection pen also contains stabilisers such as sodium phosphate, sodium chloride, and a small amount of water for injection. These are common excipients used to keep the medicine sterile and maintain its pH balance. The pen is single-use, designed for once-weekly injection. The MHRA reminds users to follow local sharps-disposal rules and to store the pen in the refrigerator until use. In clinic feedback, people frequently report that it helps to let the pen reach room temperature before injecting, as this can make the process more comfortable. If side effects occur—most often mild nausea or tiredness—they usually settle within the first few weeks, as noted in NHS obesity-medicine guidance and patient support materials. Those adjusting to the medicine often discover it helps to stay hydrated and avoid large, heavy meals during dose escalation.
How tirzepatide supports long-term metabolic health

Tirzepatide’s dual mechanism influences more than weight control. NICE’s appraisal evidence shows improvements in blood-glucose markers such as HbA1c, alongside favourable effects on cholesterol and blood pressure. International data from JAMA Network Open and New England Journal of Medicine suggest ongoing studies are exploring cardiovascular outcomes, kidney function, and even potential benefits for sleep apnoea. Many long-term users agree that it helps to think of Mounjaro as part of a broader health strategy rather than a stand-alone fix. The greatest success tends to come when lifestyle measures—balanced nutrition, movement, and regular follow-up with clinicians—are maintained in parallel.
Why this detail matters
Knowing what’s in Mounjaro clarifies how it differs from earlier weight-management options and why its effects extend beyond appetite control. The active ingredient, tirzepatide, reproduces two gut hormones that influence metabolism on several fronts, giving it a distinct scientific foundation.
By understanding that Mounjaro’s formulation works through GIP and GLP-1 pathways, people can discuss treatment decisions with realistic expectations—grounded in evidence rather than marketing claims. As NICE, NHS, and MHRA documentation all emphasise, clear knowledge of how medicines act is central to safe and effective use.






Comments